| Name | Title | Contact Details |
|---|
At Galileo Life, our goal is nothing short of a revolution in the way that healthcare is talked about and delivered. Through the establishment of a dedicated and professional network of Galileo Smart Clinics throughout the country, our vision is the development of a national-level holistic health services and wellness platform specializing in assessment, diagnostic, home-monitoring, and treatment services. The Healthcare Renaissance is here, and Galileo Life Sciences intends to herald the change in Healthcare and re-imagine Healthcare options. Galileo Life Sciences is about the pursuit of alternative solutions both in addition to, and outside of the current Western medical healthcare paradigm. We believe in taking the best of the conventional and combining it with what nature has provided - and what droves of scientific research continues to uncover and confirm - to help us heal, relieve pain, improve sleep, alleviate anxiety, increase appetite, offset the side effects of powerful pharmacological and medical treatments, and much more. Galileo Life Sciences extends an invitation to all practitioners and entrepreneurs in the Healthcare sector, to join us and become part of the bold and rapid global movement to ensure that healthcare is accessible by all in the world.
MicroConstants is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Palatin Technologies is a Cranbury, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Portage is a unique entity in the world of biotechnology, catalyzing R&D to produce more quality clinical programs and maximize potential returns.
Theravance, Inc. is focused on maximizing the potential value of the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R), with the intention of providing capital returns to stockholders. Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement with GSK, Theravance is eligible to receive the associated royalty revenues from RELVAR(R)/BREO(R) ELLIPTA(R) (fluticasone furoate/vilanterol, "FF/VI"), ANORO(R) ELLIPTA(R) (umeclidinium bromide/vilanterol, "UMEC/VI") and if approved and commercialized, VI monotherapy. Theravance is also entitled to a 15% economic interest in any future payments made by GSK under agreements entered into prior to the spin-off of Theravance Biopharma, and since assigned to Theravance Respiratory Company, LLC, relating to the combination of UMEC/VI/FF and the Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA) program, as monotherapy and in combination with other therapeutically active components, such as an inhaled corticosteroid, and any other product or combination of products that may be discovered and developed in the future under these agreements with GSK (other than RELVAR(R)/BREO(R) ELLIPTA(R), ANORO(R) ELLIPTA(R) and VI monotherapy).